Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KTTA NASDAQ:PMVP NASDAQ:SCLX NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKTTAPasithea Therapeutics$0.59-5.6%$0.73$0.28▼$2.06$15.46M0.25427,228 shs389,957 shsPMVPPMV Pharmaceuticals$1.12-5.9%$1.32$0.94▼$1.88$63.47M1.36403,189 shs314,642 shsSCLXScilex$7.00-7.7%$7.08$4.20▼$34.27$64.36M1.799,606 shs39,041 shsTCRXTScan Therapeutics$0.98-3.7%$1.10$0.88▼$2.57$66.66M1.03565,796 shs313,024 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKTTAPasithea Therapeutics-2.85%-10.82%-27.06%-22.16%-32.02%PMVPPMV Pharmaceuticals+2.59%0.00%-13.14%-27.44%+27.96%SCLXScilex+5.72%+5.13%-29.36%-10.61%+8.75%TCRXTScan Therapeutics+4.94%-5.56%-15.70%-8.93%-42.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKTTAPasithea Therapeutics$0.59-5.6%$0.73$0.28▼$2.06$15.46M0.25427,228 shs389,957 shsPMVPPMV Pharmaceuticals$1.12-5.9%$1.32$0.94▼$1.88$63.47M1.36403,189 shs314,642 shsSCLXScilex$7.00-7.7%$7.08$4.20▼$34.27$64.36M1.799,606 shs39,041 shsTCRXTScan Therapeutics$0.98-3.7%$1.10$0.88▼$2.57$66.66M1.03565,796 shs313,024 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKTTAPasithea Therapeutics-2.85%-10.82%-27.06%-22.16%-32.02%PMVPPMV Pharmaceuticals+2.59%0.00%-13.14%-27.44%+27.96%SCLXScilex+5.72%+5.13%-29.36%-10.61%+8.75%TCRXTScan Therapeutics+4.94%-5.56%-15.70%-8.93%-42.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKTTAPasithea Therapeutics 2.00Hold$3.00412.82% UpsidePMVPPMV Pharmaceuticals 2.67Moderate Buy$5.00346.43% UpsideSCLXScilex 1.00SellN/AN/ATCRXTScan Therapeutics 2.33Hold$6.00511.06% UpsideCurrent Analyst Ratings BreakdownLatest KTTA, TCRX, PMVP, and SCLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/13/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PMVPPMV Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $5.004/29/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/13/2026PMVPPMV Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/5/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/APMVPPMV PharmaceuticalsN/AN/AN/AN/A$1.97 per shareN/ASCLXScilex$30.25M1.96N/AN/A($24.94) per share-0.28TCRXTScan Therapeutics$10.32M6.22N/AN/A$2.16 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)PMVPPMV Pharmaceuticals-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%8/6/2026 (Estimated)SCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%N/ATCRXTScan Therapeutics-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%8/11/2026 (Estimated)Latest KTTA, TCRX, PMVP, and SCLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/12/2026Q1 2026PMVPPMV Pharmaceuticals-$0.41-$0.34+$0.07-$0.34N/AN/A5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million4/10/2026Q4 2025SCLXScilex-$0.47-$4.60-$4.13-$4.60$12.10 million$4.79 million3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/A3/6/2026Q4 2025PMVPPMV Pharmaceuticals-$0.40-$0.34+$0.06-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKTTAPasithea TherapeuticsN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKTTAPasithea TherapeuticsN/A35.4135.41PMVPPMV PharmaceuticalsN/A11.1411.14SCLXScilexN/A0.080.07TCRXTScan Therapeutics0.346.656.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKTTAPasithea Therapeutics23.92%PMVPPMV Pharmaceuticals90.20%SCLXScilex69.67%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipKTTAPasithea Therapeutics2.00%PMVPPMV Pharmaceuticals7.57%SCLXScilex4.11%TCRXTScan Therapeutics6.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionablePMVPPMV Pharmaceuticals5053.33 million49.30 millionOptionableSCLXScilex808.49 million8.14 millionNo DataTCRXTScan Therapeutics10065.35 million61.27 millionNot OptionableKTTA, TCRX, PMVP, and SCLX HeadlinesRecent News About These CompaniesCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3 at 9:19 AM | businesswire.comTScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net LossJune 2 at 10:11 AM | insidermonkey.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from AnalystsMay 30, 2026 | americanbankingnews.comTScan Therapeutics Expands Authorized Shares After Stockholder VoteMay 22, 2026 | tipranks.comTScan Therapeutics (NASDAQ:TCRX) Cut to "Strong Sell" at Wall Street ZenMay 9, 2026 | marketbeat.comQ2 EPS Estimates for TScan Therapeutics Cut by HC WainwrightMay 8, 2026 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits ExpectationsMay 6, 2026 | marketbeat.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%April 18, 2026 | aaii.comATScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceMarch 25, 2026 | insidermonkey.comTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03February 26, 2026 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.51%December 25, 2025 | aaii.comATScan Therapeutics (NASDAQ:TCRX) Major Shareholder Acquires $67,950.00 in StockDecember 24, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKTTA, TCRX, PMVP, and SCLX Company DescriptionsPasithea Therapeutics NASDAQ:KTTA$0.58 -0.03 (-5.63%) Closing price 04:00 PM EasternExtended Trading$0.59 +0.00 (+0.68%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.PMV Pharmaceuticals NASDAQ:PMVP$1.12 -0.07 (-5.88%) Closing price 04:00 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Scilex NASDAQ:SCLX$7.00 -0.58 (-7.65%) Closing price 04:00 PM EasternExtended Trading$6.92 -0.08 (-1.07%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.TScan Therapeutics NASDAQ:TCRX$0.98 -0.04 (-3.74%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.00 (+0.42%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
